FDA approves expanded use of AstraZeneca cancer drug

(Reuters) – The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc’s cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply